In Q3 FY2024 (ended September 30, 2024), Palvella Therapeutics reported zero revenue, a net loss of $15.8 million, and an operating loss of $14.9 million. Diluted EPS was -$1.20. Compared to the same quarter last year, revenue declined 100%, net loss widened 93%, and operating loss increased 89%.
•Revenue was $0, down 100% year-over-year.
•Net loss was $15.8 million, 93% worse than the prior year.
•Operating loss was $14.9 million, 89% higher year-over-year.
•Diluted EPS was -$1.20, a 62% decline from the prior year.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.
The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations in Phase 2 clinical trial to treat cutaneous venous malformations.
It also develops QTORIN rapamycin for the treatment of angiokeratomas and mTOR-driven skin diseases QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for patients with serious and rare genetic skin diseases. Its lead product candidate is QTORIN rapamycin, a 3.9% anhydrous topical gel currently in Phase 3 clinical trials for microcystic lymphatic malformations and Phase 2 trials for cutaneous venous malformations. The company also develops QTORIN rapamycin for angiokeratomas and other mTOR-driven skin diseases, as well as QTORIN pitavastatin for disseminated superficial actinic porokeratosis. Palvella is headquartered in Wayne, Pennsylvania, and operates in the United States.
On which stock exchange is Palvella Therapeutics (PVLA) listed and in what currency?
Palvella Therapeutics, Inc. is listed on the Nasdaq Capital Market (NasdaqGM) under the ticker symbol PVLA. The company's stock trades in U.S. dollars (USD), which is the official currency of the United States where the company is based. As a Nasdaq-listed company, Palvella is subject to the reporting and governance requirements of the U.S. Securities and Exchange Commission (SEC).
What sector and industry does Palvella Therapeutics operate in?
Palvella Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on developing therapies for rare genetic skin diseases, which falls under the broader biotechnology umbrella. Biotechnology companies like Palvella use biological processes and living organisms to develop drugs and treatments, often targeting conditions with limited existing therapies.
Where is Palvella Therapeutics headquartered and what markets does it serve?
Palvella Therapeutics is headquartered in Wayne, Pennsylvania, United States. The company primarily serves the U.S. market, as indicated by its country and region designation. Its clinical trials and development activities are focused on addressing serious and rare genetic skin diseases, which are conditions that affect patients in the United States and potentially globally. However, based on available data, the company's operations and target market are centered in the U.S.